Skip to Main content Skip to Navigation

Caractérisation d'inhibiteurs de l'entrée du Virus de l'Hépatite C

Abstract : Hepatitis C, whose causal agent is called Hepatitis C Virus (HCV), is a global health burden with about 170 million people infected. Currently, no vaccine exists again HCV and treatments are effective for only a part of infected people. Therefore, new treatments are urgently needed, as well as a better understanding of the viral life cycle.To do so, we studied the entry process of HCV in its targets cells through the characterisation of HCV entry inhibitors. Firstly, we have shown that EWI-2wint, a natural inhibitor of HCV entry, blocks this process by changing the partitionning of CD81, one of the HCV receptors. In addition, we have studied the effect of monensin on HCV infection and found that this pharmacological inhibitor impairs a late step of HCV entry.Altogether, our results allow a better understading of the HCV entry process and open the way to the development of new therapeutic agents.
Document type :
Complete list of metadatas
Contributor : Abes Star :  Contact
Submitted on : Tuesday, July 9, 2013 - 5:22:13 PM
Last modification on : Friday, October 23, 2020 - 4:44:32 PM
Long-term archiving on: : Thursday, October 10, 2013 - 4:13:15 AM


Version validated by the jury (STAR)


  • HAL Id : tel-00842934, version 1



Julie Potel. Caractérisation d'inhibiteurs de l'entrée du Virus de l'Hépatite C. Médecine humaine et pathologie. Université du Droit et de la Santé - Lille II, 2012. Français. ⟨NNT : 2012LIL2S037⟩. ⟨tel-00842934⟩



Record views


Files downloads